Yujie Wang

Xinjiang Medical University

SCHOLARLY PAPERS

1

DOWNLOADS

70

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Deutenzalutamide (Deuterated Enzalutamide), a Novel Androgen Receptor Inhibitor after Failure of Docetaxel and Abiraterone in Metastatic Castrate Resistant Prostate Cancer (mCRPC): Results from Therandomized Phase III HC-1119-04 Trial

Number of pages: 17 Posted: 28 Oct 2024
Fudan University, Hinova Pharmaceuticals Inc, Nanjing Medical University - Jiangsu Province Hospital, Tianjin Medical University, Chongqing Cancer Hospital, Government of the People's Republic of China - Sichuan Provincial People's Hospital, Fudan University - Zhongshan Hospital, Hangzhou Medical College - Zhejiang Provincial People's Hospital, Peking Union Medical College, Zhejiang University, Zhejiang Cancer Hospital, Shanxi Medical University, Xinjiang Medical University, Central South University - Hunan Cancer Hospital, Fudan University, Shanghai Jiao Tong University (SJTU), Harbin Medical University, Shandong University, Xinjiang Medical University, Soochow University, Hinova Pharmaceuticals Inc, Hinova Pharmaceuticals Inc, Fudan University - Department of Oncology and Independent
Downloads 70 (730,018)

Abstract:

Loading...

Prostate cancer, mCRPC, androgen receptor (AR), clinical trial, phase 3